Allergan, Inc.

Sandhya Rao

Thomas C Malone

Rong Yang

Daniel W Gil

Sougato Boral

Shimiao Wang

John E Donello

Larry Allen Wheeler

Sheila X Zhou

Mingting Tian

Edwin U Padillo

Jyotirmoy Kusari

Robert M Burk

David W Old

Tien T Duong

Veena Viswanath

Santosh C Sinha

Ling Li

Julie Wurster

Jeremiah H Nguyen

Clarence Eugene Hull, Iii

Richard Yee

Karen M Kedzie

Christopher D Hein

Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:  The compounds are useful for treating inflammatory and autoimmune diseases.

3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof

This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, R, Rand X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors

Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a compound selected from the group consisting of olanzapine, certain of its metabolites, clozapine, and n-desmethyl clozapine.

Methods for treating diseases of the retina

This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R, R, R, R, R, Rand Rare as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.

Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2

Disclosed herein are methods of screening compounds that modulate G-protein coupled receptors. The assays are performed at temperatures of between about 25&#xb0; C. and 40&#xb0; C.

Methods for detecting receptor modulator activity

Growing community of inventors

Irvine, CA, United States of America

Sandhya Rao